This newest twist in the Lykos Therapeutics saga threatens a major overhaul of the company’s system and route, with Musk ally and billionaire Trader Antonio Gracias appearing to want to get the corporate again toward its nonprofit drug progress roots and a more Doblinite philosophy., James writes about why so Lots of people — together with hers